Differing responses of hamsters to infection by vesicular stomatitis virus Indiana and New Jersey serotypes
- PMID: 2414943
- DOI: 10.1016/0168-1702(85)90003-6
Differing responses of hamsters to infection by vesicular stomatitis virus Indiana and New Jersey serotypes
Abstract
Intraperitoneal injection of vesicular stomatitis virus, New Jersey serotype (VSV-NJ), into inbred LSH hamsters resulted in an inapparent infection and survival of the majority of the animals. Infectivity titrations of tissues from VSV-NJ-infected hamsters showed that little or no virus was present following infection. The few animals that died from VSV-NJ succumbed to neurological disease. This is in contrast to our previous work where we found that LSH hamsters are exquisitely sensitive to i.p. infection by VSV, Indiana serotype (VSV-IND), and that large amounts of VSV-IND could be detected in tissues. The 50% lethal doses of VSV-NJ and VSV-IND for LSH hamsters are approximately 10(7) pfu and 1 pfu, respectively. When peritoneal cells from LSH hamsters were infected in vitro with both VSV serotypes, the yields of VSV-NJ consistently were lower than yields of VSV-IND. The growth of the two serotypes in fibroblast and epithelial cell lines of hamster origin was similar. VSV-NJ was not more efficient than VSV-IND in inducing interferon in vitro or in vivo, and there appeared to be no difference in the sensitivities of the two serotypes to the antiviral activity of hamster interferon. Thus, i.p. infection with less than 10(7) pfu of VSV-NJ is avirulent for LSH hamsters and this avirulence may be due, in part, to partial intrinsic resistance of peritoneal macrophages to infection by VSV-NJ. When four LSH hamsters that had been immunized with VSV-NJ were challenged with 10(6) LD50 of VSV-IND, three of the four animals survived. Despite the fact that neutralizing antibodies to VSV-NJ did not cross-neutralize VSV-IND, five out of five LSH hamsters were protected by passive transfer of 1 ml of immune hamster anti-VSV-NJ antiserum prior to challenge with VSV-IND. This suggests an important role for non-neutralizing antibodies.
Similar articles
-
Antibodies against the two serotypes of vesicular stomatitis virus measured by enzyme-linked immunosorbent assay: immunodominance of serotype-specific determinants and induction of asymmetrically cross-reactive antibodies.J Virol. 1987 Aug;61(8):2509-14. doi: 10.1128/JVI.61.8.2509-2514.1987. J Virol. 1987. PMID: 2439706 Free PMC article.
-
Localization of T helper cell epitopes in the vesicular stomatitis virus: the nucleoprotein is responsible for serotype cross-reactive T help.Viral Immunol. 1994;7(3):103-11. doi: 10.1089/vim.1994.7.103. Viral Immunol. 1994. PMID: 7541205
-
Mediators of protection against lethal systemic vesicular stomatitis virus infection in hamsters: defective interfering particles, polyinosinate-polycytidylate, and interferon.Infect Immun. 1982 Aug;37(2):679-86. doi: 10.1128/iai.37.2.679-686.1982. Infect Immun. 1982. PMID: 6180986 Free PMC article.
-
An enzyme-linked immunosorbent assay for the detection of bovine antibodies to vesicular stomatitis virus.Am J Vet Res. 1986 Jul;47(7):1507-12. Am J Vet Res. 1986. PMID: 3017162
-
Emergence and re-emergence of vesicular stomatitis in the United States.Virus Res. 2002 May 10;85(2):211-9. doi: 10.1016/s0168-1702(02)00026-6. Virus Res. 2002. PMID: 12034487 Review.
Cited by
-
Oncolytic viruses in cancer therapy.Cancer Lett. 2007 Sep 8;254(2):178-216. doi: 10.1016/j.canlet.2007.02.002. Epub 2007 Mar 23. Cancer Lett. 2007. PMID: 17383089 Free PMC article. Review.
-
Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.Animals (Basel). 2021 Jul 8;11(7):2039. doi: 10.3390/ani11072039. Animals (Basel). 2021. PMID: 34359167 Free PMC article. Review.
-
Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory.Virol Sin. 2024 Jun;39(3):434-446. doi: 10.1016/j.virs.2024.03.010. Epub 2024 Mar 29. Virol Sin. 2024. PMID: 38556051 Free PMC article.
-
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.J Virol. 2003 Aug;77(16):8843-56. doi: 10.1128/jvi.77.16.8843-8856.2003. J Virol. 2003. PMID: 12885903 Free PMC article.
-
A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.Viruses. 2020 Aug 22;12(9):923. doi: 10.3390/v12090923. Viruses. 2020. PMID: 32842671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical